1022 related articles for article (PubMed ID: 35299965)
21. Anti-Müllerian hormone as a diagnostic tool for PCOS under different diagnostic criteria in an unselected population.
Bozdag G; Mumusoglu S; Coskun ZY; Yarali H; Yildiz BO
Reprod Biomed Online; 2019 Sep; 39(3):522-529. PubMed ID: 31182353
[TBL] [Abstract][Full Text] [Related]
22. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone.
Lauritsen MP; Bentzen JG; Pinborg A; Loft A; Forman JL; Thuesen LL; Cohen A; Hougaard DM; Nyboe Andersen A
Hum Reprod; 2014 Apr; 29(4):791-801. PubMed ID: 24435776
[TBL] [Abstract][Full Text] [Related]
23. Metabolic risk assessment of Indian women with polycystic ovarian syndrome in relation to four Rotterdam criteria based phenotypes.
Tripathy P; Sahu A; Sahu M; Nagy A
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():60-65. PubMed ID: 29550643
[TBL] [Abstract][Full Text] [Related]
24. Phenotypic variation in anti-Mullerian hormone (AMH) production per follicle in women with polycystic ovary syndrome (PCOS) and isolated polycystic ovarian morphology (PCOM): an observational cross-sectional study.
Bhide P; Kulkarni A; Dilgil M; Dhir P; Shah A; Gudi A; Homburg R
Gynecol Endocrinol; 2017 Oct; 33(10):801-806. PubMed ID: 28454499
[TBL] [Abstract][Full Text] [Related]
25. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in the Croatian population.
Baldani DP; Skrgatić L; Simunić V; Zlopasa G; Canić T; Trgovcić I
Coll Antropol; 2013 Jun; 37(2):477-82. PubMed ID: 23940993
[TBL] [Abstract][Full Text] [Related]
26. Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome.
Panidis D; Tziomalos K; Macut D; Delkos D; Betsas G; Misichronis G; Katsikis I
Fertil Steril; 2012 Feb; 97(2):494-500. PubMed ID: 22192350
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population.
Pehlivanov B; Orbetzova M
Gynecol Endocrinol; 2007 Oct; 23(10):604-9. PubMed ID: 17852429
[TBL] [Abstract][Full Text] [Related]
28. Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS Prevalence Study.
Hosseinpanah F; Barzin M; Keihani S; Ramezani Tehrani F; Azizi F
Clin Endocrinol (Oxf); 2014 Jul; 81(1):93-9. PubMed ID: 24428207
[TBL] [Abstract][Full Text] [Related]
29. The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum.
Rosenfield RL
J Pediatr Adolesc Gynecol; 2015 Dec; 28(6):412-9. PubMed ID: 25840648
[TBL] [Abstract][Full Text] [Related]
30. The Prevalence of Metabolic Syndrome in the Different Phenotypes of Polycystic Ovarian Syndrome.
Tavares A; Rêgo Barros RC
Rev Bras Ginecol Obstet; 2019 Jan; 41(1):37-43. PubMed ID: 30716785
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Anti-müllerian Hormone (AMH) and Hormonal Assays for Phenotypic Classification of Polycystic Ovary Syndrome.
Ozay AC; Emekcı Ozay O; Gulekli B
Ginekol Pol; 2020; 91(11):661-667. PubMed ID: 33301159
[TBL] [Abstract][Full Text] [Related]
32. Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria.
Yilmaz M; Isaoglu U; Delibas IB; Kadanali S
J Obstet Gynaecol Res; 2011 Aug; 37(8):1020-6. PubMed ID: 21481088
[TBL] [Abstract][Full Text] [Related]
33. Polycystic Ovary Syndrome.
Azziz R
Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
[TBL] [Abstract][Full Text] [Related]
34. The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females.
Mehrabian F; Khani B; Kelishadi R; Kermani N
J Res Med Sci; 2011 Jun; 16(6):763-9. PubMed ID: 22091305
[TBL] [Abstract][Full Text] [Related]
35. [Clinical, hormonal and metabolic characteristics of different phenotypes of polycystic ovary syndrome, in Bulgarian population].
Kavardzhikova S; Pechlivanov B
Akush Ginekol (Sofiia); 2010; 49(4):32-7. PubMed ID: 20734639
[TBL] [Abstract][Full Text] [Related]
36. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis.
Lie Fong S; Laven JSE; Duhamel A; Dewailly D
Hum Reprod; 2017 Aug; 32(8):1723-1731. PubMed ID: 28854584
[TBL] [Abstract][Full Text] [Related]
37. PCOS: a diagnostic challenge.
Azziz R
Reprod Biomed Online; 2004 Jun; 8(6):644-8. PubMed ID: 15169578
[TBL] [Abstract][Full Text] [Related]
38. Recommendations for epidemiologic and phenotypic research in polycystic ovary syndrome: an androgen excess and PCOS society resource.
Azziz R; Kintziger K; Li R; Laven J; Morin-Papunen L; Merkin SS; Teede H; Yildiz BO
Hum Reprod; 2019 Nov; 34(11):2254-2265. PubMed ID: 31751476
[TBL] [Abstract][Full Text] [Related]
39. Implications of the 2014 Androgen Excess and Polycystic Ovary Syndrome Society guidelines on polycystic ovarian morphology for polycystic ovary syndrome diagnosis.
Christ JP; Gunning MN; Fauser BCJM
Reprod Biomed Online; 2017 Oct; 35(4):480-483. PubMed ID: 28733169
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of Polycystic Ovary Syndrome Phenotypes Using Updated Criteria for Polycystic Ovarian Morphology: An Assessment of Over 100 Consecutive Women Self-reporting Features of Polycystic Ovary Syndrome.
Clark NM; Podolski AJ; Brooks ED; Chizen DR; Pierson RA; Lehotay DC; Lujan ME
Reprod Sci; 2014 Aug; 21(8):1034-1043. PubMed ID: 24520081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
